This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Saving for retirement in a 401(k) plan is a great choice. But socking money away and hoping for the best isn’t actually a strategy. A better idea is to have a financial plan to accompany that account.
PRU PRH PFK 3772 PJH
NEW YORK: Wall Street stocks finished slightly lower on Friday (Jul 20) as President Donald Trump's latest tariff threats and attack on the Federal Reserve kept a lid on gains despite largely solid earnings.
HON PRU HON PRH PFK PJH
Champion dividend stocks sustained over 25 annual dividend increases, Contenders 10-24, and Challengers 5-9. WallStars show >.5% price target upsides.
HEP PM GEO PFG HMLP GLOP PRU EQM NYLD SUN NYLD.A PRU GLOP.PRA WLK PFK GLOP.PRB VLP MORN SIR PRH LAZ DGICA HMLP.PRA DGICB PJH
Prudential Investments, a segment of Prudential Financial, Inc., offers a wide range of funds including both equity and fixed-income, and open- and closed-end funds. The company, which has around $74 billion of assets under management, currently offers services across 41 countries and territories including the United States, Asia and Europe. Investment professionals of the company are also involved in managing assets of major corporations and pension funds throughout the globe.
PRU GTT PRH PFK PJH
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PRU PRH PFK CSCO PJH
43 of 101 S&P 500 Index top-yield dividend stocks were labeled as "safer" for dividends because they showed positive 1-year returns and free cash-flow yields greater than their dividend yields as of 7/9/18.
DLR.PRH DLR.PRG HCN PM DLR.PRJ PFG DLR.PRI WELL.PRI O.PRF MET STX OPRF PRU VZA IP CUKPF CCL WELL ABBV VTR PRU F INPAP PFK O CCL HCN.PRJ CUK HCN.PRI SPG.PRJ PRH CVX VZ VTRB SPG ABBV DLR QCOM DLR.PRC DLR.PRF PJH IVZ
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to PRH / Prudential Financial, 5.70% Junior Subordinated Bonds due 3/15/2053 on message board site Silicon Investor.
|PRHC: Province Healthcare|
as of ET